Trial reportHaematologica2018
Melphalan 140 mg/m
Abstract readClinical Trial
In one paragraph
Trial report in Haematologica, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 43 papers.
0numbers the graph read from it
0cells of the map it votes in
43citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
43 citing papers in PubMed.
- Autologous stem cell transplantation is safe and effective for fit older myeloma patients: exploratory results from the Myeloma XI trial.Haematologica · 2022Trial
- Tandem autologous hematopoietic cell transplantation with sequential use of total marrow irradiation and high-dose melphalan in multiple myeloma.Bone marrow transplantation · 2021Trial
- Lower glomerular filtration rate predicts increased hepatic and mucosal toxicity in myeloma patients treated with high-dose melphalan.International journal of hematology · 2018Trial
- Determinants of Long-Term Benefit From High Dose Melphalan With Autologous Stem Cell Transplant in AL Amyloidosis.American journal of hematology · 2026Article
- Survival and Renal Recovery in Newly Diagnosed Multiple Myeloma Patients Presenting With Dialysis-Requiring Severe Renal Impairment.European journal of haematology · 2026Article
- Reduced dose versus standard melphalan conditioning for autologous stem cell transplantation in multiple myeloma: a single-center retrospective study.Annals of hematology · 2026Article
- Is Less "Sufficient" and "Safe" in the MRD Era - Outcomes of Autologous Stem-Cell Transplant as per Melphalan Dose in Patients with Multiple Myeloma.Blood cancer journal · 2026Article
- The impact of age on survival and excess mortality after autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.Haematologica · 2026Article
- Reduced-versus Standard-dose Melphalan as Single-agent Conditioning Regimen in Auto HSCT for Multiple Myeloma: A Systematic Review and Meta-Analysis.Blood cell therapy · 2025Article
- Retrospective Study to Compare Outcomes in 159 Patients Undergoing First Autologous Stem Cell Transplantation for Myeloma Treated with Melphalan 140 mg/m² or 200 mg/m².Annals of transplantation · 2025Article
- Autologous stem cell transplantation in patients older than 65 years with multiple myeloma: a real-world study.Hematology, transfusion and cell therapy · 2024Article
- Global characteristics and outcomes of autologous hematopoietic stem cell transplantation for newly diagnosed multiple myeloma: A study of the worldwide network for blood and marrow transplantation (WBMT).American journal of hematology · 2024Article
- Outcomes of melphalan 140 mg/mEJHaem · 2024Article
- Melphalan-associated encephalopathy following autologous stem cell transplant: a transplanter's nightmare!Blood cell therapy · 2024Article
- In the era of Bortezomib-based Induction, intensification of Melphalan-based conditioning with Bortezomib does not improve Survival Outcomes in newly diagnosed Multiple Myeloma: a study from the Chronic Malignancies Working Party of the EBMT.Bone marrow transplantation · 2024Article
- Optimizing high dose melphalan.Blood reviews · 2024Review
- Real-world prognostic factors in autotransplanted multiple myeloma patients with severe renal impairment: study of the Polish Myeloma Study Group.Archives of medical science : AMS · 2024Article
- Clinical factors associated with autologous stem cell transplantation outcomes in multiple myeloma: upfront transplant with MEL200 remains the standard of care.Annals of hematology · 2024Article
- The Impact of Renal Impairment in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation With Melphalan Conditioning.Journal of hematology · 2023Article
- An early post-transplant relapse prediction score in multiple myeloma: a large cohort study from the chronic malignancies working party of EBMT.Bone marrow transplantation · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
25 authors.
Holger W AunerDepartment of Medicine, Imperial College London, UK holger.auner04@imperial.ac.uk.
Simona IacobelliDepartment of Biology, Tor Vergata University of Rome, Italy.
Giulia SbianchiDepartment of Biology, Tor Vergata University of Rome, Italy.
Cora Knol-BoutEBMT Data Office, Leiden, the Netherlands.
Didier BlaiseInstitut Paoli Calmettes, Marseille, France.
Nigel H RussellNottingham University, UK.
Jane F ApperleyDepartment of Medicine, Imperial College London, UK.
David PohlreichCharles University Hospital, Prague, Czech Republic.
Paul V BrowneSt. James's Hospital, Trinity College Dublin, Ireland.
Guido KobbeHeinrich Heine Universität, Düsseldorf, Germany.
Cecilia IsakssonUmeå University Hospital, Sweden.
Stig LenhoffSkåne University Hospital, Lund, Sweden.
Christof ScheidUniversity of Cologne, Germany.
Cyrille TouzeauCHU Nantes, France.
Esa JantunenKuopio University Hospital, Finland.
Achilles AnagnostopoulosGeorge Papanicolaou General Hospital, Thessaloniki, Greece.
Ibrahim Yakoub-AghaCHU de Lille, LIRIC, INSERM U995, France.
Alina TanaseFundeni Clinical Institute, Bucharest, Romania.
Nicolaas SchaapRadboud University Medical Centre, Nijmegen, the Netherlands.
Wieslaw Wiktor-JedrzejczakMedical University, Warsaw, Poland.
Marta KrejciUniversity Hospital Brno, Czech Republic.
Stefan O SchönlandUniversity of Heidelberg, Germany.
Curly MorrisQueens University of Belfast, Northern Ireland.
Laurent GarderetHôpital Saint-Antoine, Paris, France.
Nicolaus KrögerUniversity Hospital Hamburg-Eppendorf, Hamburg, Germany.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Melphalan at a dose of 200 mg/m
Indexed as
AdultAgedDose-Response Relationship, DrugFemaleHematopoietic Stem Cell TransplantationHumansMaleMelphalanMiddle AgedMultiple MyelomaRecurrenceSurvival AnalysisTransplantation, AutologousTransplantation ConditioningTreatment OutcomeMelphalan
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.